In clinical trials, tirzepatide has demonstrated dose‐dependent efficacy in people with obesity, T2D or both, in terms of glycated haemoglobin (HbA1c) level reduction and bodyweight reduction compared with placebo, GLP‐1 receptor agonists and basal insulin.11, 12. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.